E. coli O157

If you have bloody diarrhea, severe stomach pain, or sudden gastroenteritis that does not feel like a typical stomach bug, the question your body is asking is: what is actually causing this? E. coli O157 is one of the few gut infections that can quickly turn from diarrhea into kidney failure, and identifying it fast changes what doctors do next, including whether you should avoid certain antibiotics that may make things worse.

This stool test uses PCR (a method that finds and copies tiny pieces of bacterial DNA) to detect E. coli O157 directly in your sample. It catches infections that older culture-based tests miss, returns results in hours rather than days, and tells your clinician whether you are dealing with this particular high-risk strain.

What This Test Actually Detects

The lab is looking for specific bacterial genes, usually rfbE (which marks the O157 serogroup), and often Shiga toxin genes (stx1 and stx2) that explain why this strain is so dangerous. Detecting these gene sequences in your stool means E. coli O157 or a closely related Shiga toxin-producing E. coli (STEC) is present in your gut. It is not a marker your own body makes. It is a direct fingerprint of a pathogen.

Healthy cattle are the main reservoir for this bacterium and carry it without becoming sick themselves. Humans typically pick it up through undercooked ground beef, unpasteurized milk or juice, contaminated water or produce, or direct contact with farm animals or infected people. Once inside your gut, the bacteria release Shiga toxins that can damage the lining of the colon and, in serious cases, the small blood vessels in the kidneys.

Why This Infection Matters

E. coli O157 infection can range from a few days of diarrhea to a medical emergency. The clinical picture commonly includes bloody diarrhea and hemorrhagic colitis (severe bleeding from inflamed intestines). The most feared complication is hemolytic uremic syndrome (HUS), a condition where the toxins damage red blood cells and shut down kidney function.

Across the broader literature, roughly 5 to 10 percent of people with STEC gastroenteritis develop HUS, with rates climbing to 20 percent or higher during outbreaks. O157 strains carry a higher risk than non-O157 strains. In a small Northern California single-center study of 14 O157 patients, 6 (42.9 percent) developed HUS, compared with 1 of 17 (5.8 percent) non-O157 STEC patients; that figure is striking but should be read as a small-cohort estimate, not a population-level rate. The risk is highest in young children, older adults, and people whose infection presents with vomiting, bloody diarrhea, or rapidly worsening symptoms.

Beyond HUS, severe outcomes can include acute kidney failure, neurologic complications, long-term kidney dysfunction, blood pressure problems, and in some cases death. Long-term follow-up studies estimate that roughly 25 to 50 percent of people who develop HUS have some kidney-related sequelae years later, including reduced glomerular filtration, proteinuria, or hypertension, though the majority of these are mild and only a smaller subset progress to advanced chronic kidney disease.

Hemolytic Uremic Syndrome Risk

HUS develops in some people days after the diarrhea starts, as Shiga toxins move from the gut into the bloodstream. In a UK retrospective cohort, several factors significantly raised the odds of HUS in people with O157 infection.

Source: Disease severity of Shiga toxin-producing E. coli O157 and factors influencing the development of typical HUS, BMJ Open 2016. The 4.08-fold estimate is from this single UK cohort. A 2025 meta-analysis of 23 studies and 17,975 patients reported a pooled odds ratio of about 2.37 (95% CI 1.79 to 3.15), and a US FoodNet case-control study reported about 2.80 (95% CI 1.14 to 6.89). The direction is consistent across studies even though the magnitude varies.

What this means for you: confirming O157 quickly through stool PCR is not just a diagnostic exercise. It directly changes whether antibiotics should be used or avoided, whether hydration and kidney function need close monitoring, and whether your local public health authority should be alerted to a possible outbreak.

Why PCR Beats Older Stool Tests

For decades, labs relied on a special agar (called sorbitol-MacConkey) that grows O157 selectively. The problem is that this method misses non-O157 STEC strains entirely and can also miss low-level O157 infections. Toxin immunoassays (EIA), which look for the Shiga toxin protein, are also less sensitive than PCR.

In the same pediatric study of 2,386 samples, only 54.7% of PCR-positive specimens were positive by the toxin immunoassay. PCR identified 35 O157 cases and 18 non-O157 STEC cases that O157-focused culture would have largely missed. A separate validation study reported PCR sensitivity of 100% (95% CI 89.1% to 100%) and specificity of 98.5% (95% CI 90.6% to 99.9%) for STEC detection from stool, and a systematic review and meta-analysis of 22 PCR studies estimated a pooled sensitivity of 1.00, compared with about 0.68 for enzyme immunoassays.

Speed matters too. In one large pediatric comparison, the median time from sample collection to result was 18 hours with a syndromic PCR panel versus 47 hours with culture. Faster results mean faster decisions about hydration, hospitalization, and whether to stop antibiotics that were started empirically.

How Results Should Be Interpreted

A positive PCR for E. coli O157 in stool means the assay detected DNA from this organism in your sample. In someone with diarrhea, especially bloody diarrhea, that is strong evidence of active infection. The clinical decisions that follow depend on symptoms, age, kidney function, and how long you have been sick, not just on the lab line itself.

A negative PCR makes O157 infection very unlikely as the cause of your current symptoms, but does not rule out other diarrheal pathogens. Many modern PCR workflows run as a panel that simultaneously tests for Salmonella, Shigella, Campylobacter, Giardia, Cryptosporidium, and viruses, which is why your clinician may order this test as part of a broader workup rather than in isolation.

Reconciling PCR and Culture

PCR positivity does not always mean a viable organism can be grown back from your stool. In one Dutch national study, only about 38% of PCR-positive stools yielded an isolate using standard selective methods, while a Finnish program using non-selective culture recovered isolates from about 90% of PCR-positive samples. Lower Ct values (a measure of how much bacterial DNA is in the sample) generally indicate higher bacterial load and correlate with successful culture recovery. For E. coli O157, culture-positive stools had a mean Ct of 27.85 versus 35.96 in culture-negative stools.

This is not a paradox. PCR is more sensitive than culture, so it can detect low-burden infections and DNA from recently shed or non-viable organisms. The two tests answer slightly different questions: PCR asks whether the genes are present, culture asks whether a live organism can be grown. For your personal diagnosis, PCR is sufficient. For public health investigations and outbreak tracking, culture is still needed to provide isolates for strain typing and whole genome sequencing.

When Results Can Be Misleading

Most testing distortions in stool PCR come from sample handling and bacterial load rather than from the person being tested. A few things are worth knowing.

• Low bacterial load: if your infection is at the very beginning or already resolving, the amount of bacterial DNA may be low, producing a high Ct value. Culture may fail in these cases even though PCR is positive.
• Sample storage: stools positive by PCR but stored at very cold temperatures before culture had lower coliform recovery than those stored at refrigerator temperature, which affects culture rather than PCR but can complicate confirmation.
• Antibiotics before testing: taking antibiotics before the sample is collected can reduce both bacterial load and culture recovery. PCR may still detect DNA but the picture becomes harder to interpret.
• Asymptomatic carriage: some people without diarrhea can carry STEC and test positive. Recent genomic work found many strains in asymptomatic carriers have lower virulence profiles than strains from symptomatic patients, so a positive in someone without symptoms requires clinical judgment rather than automatic alarm.

The Decision Pathway After a Positive Result

A positive E. coli O157 stool PCR should trigger a specific set of next steps. First, your clinician should review symptoms and rehydration status, since dehydration is the main early threat and early fluid infusion has been shown to reduce the risk of central nervous system complications, dialysis, and long-term sequelae. Second, antibiotics should generally be avoided or stopped, especially beta-lactams in children, because of the link to HUS. Third, kidney function and blood counts should be monitored over the following days, particularly in children under 5 and adults with bloody diarrhea.

Public health reporting is also part of the pathway. E. coli O157 is a reportable infection in most jurisdictions, and your stool sample may be sent to a public health laboratory for culture, serotyping, and whole genome sequencing to determine whether your case is connected to a wider outbreak. Household contacts with symptoms may need their own testing. People who handle food, work in healthcare, or care for young children may face temporary work restrictions until clearance is documented.

Retesting and Clearance

Unlike chronic biomarkers, this is not a number to track over years. The test is done when there is reason to suspect an active infection. Once positive, the practical question is when shedding has stopped, which matters most for people in high-exposure roles like food handling or daycare. In a Finnish follow-up program, two consecutive PCR-negative stool samples were considered sufficient to demonstrate clearance, with only about 2 percent of cases later turning positive again after two negatives. Median shedding lasted about 22 to 23 days in that study, and a separate UK study reported a median of around 32 days. Your clinician or local public health team will guide the specific timing based on your role and exposure risk.

For most people without ongoing exposure concerns, no routine retesting is needed once symptoms resolve. If symptoms persist or kidney function worsens after the initial diagnosis, the focus shifts from repeating the PCR to monitoring blood counts, creatinine, and urine output for early signs of HUS.